460 Participants Needed

AI-Generated Summaries for Eye Disease

PT
Overseen ByPrashant Tailor, MD
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Los Angeles
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications.

What data supports the effectiveness of the treatment AI-Generated Plain Language Summaries for eye disease?

The study on AI-assisted diabetic retinopathy screening in Australia shows that AI systems can be accurate and well-accepted by patients and clinicians, suggesting that AI-generated summaries could also be effective in helping patients understand eye disease information.12345

How is the AI-Generated Plain Language Summaries treatment different from other treatments for eye disease?

The AI-Generated Plain Language Summaries treatment is unique because it uses artificial intelligence to create easy-to-understand summaries of complex medical information, helping patients better understand their eye conditions and treatments. This approach differs from traditional treatments that focus on medical interventions, as it aims to improve patient comprehension and engagement.678910

What is the purpose of this trial?

This clinical trial is testing whether plain language summaries made by artificial intelligence help people understand their eye doctor's notes better. Adults receiving eye care at the Jules Stein Eye Institute will get either the usual medical notes or a note with the addition of an AI-generated summary that explains the information in simple, everyday words. Participants will then answer a short survey and receive a follow-up call to share how clear the information was, how well they understood their diagnosis and treatment, and whether they feel more confident about their care. The goal is to find out if these plain language summaries can make it easier for people to understand their eye care and improve communication between patients and health care providers.

Research Team

PT

Prashant Tailor, MD

Principal Investigator

University of California, Los Angeles

Eligibility Criteria

This trial is for English-speaking adults who are receiving eye care at the Jules Stein Eye Institute. It's designed to help those who may struggle with understanding medical jargon, possibly including patients with aphasia or other communication difficulties.

Inclusion Criteria

Receiving ophthalmology care at the Jules Stein Eye Institute
Able to provide informed consent

Exclusion Criteria

Prisoners or wards of the state
I am unable to understand and agree to the study details on my own.
I do not have conditions like dementia that affect my understanding.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

1-2 weeks

Intervention

Participants receive either standard ophthalmology notes or notes with an AI-generated plain language summary

1 day
1 visit (in-person)

Immediate Post-Visit Assessment

Participants complete a survey to assess comprehension and satisfaction immediately after their clinic visit

1 day

Follow-up

Participants receive a follow-up telephone interview to assess retention of information and provide additional feedback

1 week
1 call (telephone)

Treatment Details

Interventions

  • AI-Generated Plain Language Summaries
Trial Overview The study is testing AI-generated summaries that translate ophthalmology notes into plain language. Participants will be randomly given either standard medical notes or ones with an AI summary, and their comprehension and confidence in care will be assessed through surveys and follow-up calls.
Participant Groups
2Treatment groups
Experimental Treatment
Active Control
Group I: SON + AI-Generated Plain Language SummariesExperimental Treatment1 Intervention
Participants in this arm receive the standard ophthalmology notes plus an AI-generated plain language summary, reviewed for accuracy before distribution. They will complete the same surveys to assess whether the additional summary improves their understanding and satisfaction compared to the control group.
Group II: Standard Ophthalmology Notes (SON) OnlyActive Control1 Intervention
Participants in this arm receive the standard ophthalmology notes typically provided after their clinic visit, with no additional plain language summary. They will complete surveys that measure their comprehension and satisfaction with the visit notes.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Los Angeles

Lead Sponsor

Trials
1,594
Recruited
10,430,000+

Findings from Research

The Total Visual Acuity Extraction Algorithm (TOVA) successfully automates the extraction of visual acuity data from unstructured clinical notes, achieving a 95% concordance rate with manual extraction in a validation study of 644 notes.
TOVA demonstrated high reliability and accuracy, with interrater reliability statistics indicating strong agreement and a Pearson correlation coefficient of 0.983, making it a valuable tool for efficiently processing large volumes of ophthalmology data.
Validation of the Total Visual Acuity Extraction Algorithm (TOVA) for Automated Extraction of Visual Acuity Data From Free Text, Unstructured Clinical Records.Baughman, DM., Su, GL., Tsui, I., et al.[2022]
The study analyzed 14,537 cataract surgeries over 32 months using electronic health record (EHR) data, demonstrating that EHR can effectively evaluate surgical outcomes for both resident and attending surgeons.
Results showed that 74% of resident surgeries had better postoperative visual acuity, with no significant difference in outcomes between residents and attending surgeons, indicating that residents can achieve comparable surgical results despite starting with poorer baseline visual acuity.
Assessing Resident Cataract Surgical Outcomes Using Electronic Health Record Data.Xiao, G., Srikumaran, D., Sikder, S., et al.[2023]
A survey of 466 patients with wet age-related macular degeneration revealed that the most important factors influencing their treatment preferences were clarity of vision, treatment effects on symptoms, and quality of vision, highlighting the significance of visual outcomes in their care.
The study demonstrated that patients actively engage in their treatment management, as indicated by their high levels of knowledge and confidence, which can guide future clinical development to better align with patient needs.
Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis.Skelly, A., Taylor, N., Fasser, C., et al.[2023]

References

Validation of the Total Visual Acuity Extraction Algorithm (TOVA) for Automated Extraction of Visual Acuity Data From Free Text, Unstructured Clinical Records. [2022]
Assessing Resident Cataract Surgical Outcomes Using Electronic Health Record Data. [2023]
Patient Preferences in the Management of Wet Age-Related Macular Degeneration: A Conjoint Analysis. [2023]
Real-world artificial intelligence-based opportunistic screening for diabetic retinopathy in endocrinology and indigenous healthcare settings in Australia. [2021]
Diabetic Retinopathy Telemedicine Outcomes With Artificial Intelligence-Based Image Analysis, Reflex Dilation, and Image Overread. [2023]
Age-related macular degeneration: what do patients find on the internet? [2021]
Performance of ChatGPT in Diagnosis of Corneal Eye Diseases. [2023]
Simultaneous screening and classification of diabetic retinopathy and age-related macular degeneration based on fundus photos-a prospective analysis of the RetCAD system. [2022]
Artificial intelligence in retinal disease: clinical application, challenges, and future directions. [2023]
Big data in corneal diseases and cataract: Current applications and future directions. [2023]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security